Probiotics for IBS: What the Clinical Evidence Actually Shows
Disclaimer: This content is for informational purposes only and is not medical advice. Consult a healthcare professional before starting any supplement. Individual results vary. If you have IBS, consult a gastroenterologist or dietitian before starting any supplement regimen.
IBS (Irritable Bowel Syndrome) affects approximately 10-15% of the global population (Drossman et al, Gastroenterology 2016). It is a functional gut disorder characterised by recurring abdominal pain and altered bowel habits — constipation (IBS-C), diarrhoea (IBS-D), or both (IBS-M). The cause is not fully understood; current evidence implicates gut-brain axis dysregulation, post-infectious gut changes, and microbiome composition.
Probiotics are one of the most researched interventions for IBS. The evidence is real — and genuinely more complicated than most supplement sites acknowledge.
The Fundamental Problem: IBS Is Not One Disease
The single most important context for understanding IBS probiotic research: IBS-D, IBS-C, and IBS-M are different clinical presentations with different mechanisms, and the probiotic strains that benefit one subtype may have no effect on another.
A systematic review in Gut (Ford et al, 2018, PMID 30082268) pooled 53 RCTs of probiotics for IBS. The overall finding: probiotics likely reduce IBS symptom severity vs placebo. But the review also found significant heterogeneity — results varied substantially across trials, largely because different trials used different strains for different patient populations.
This means: asking “do probiotics work for IBS?” is like asking “do antibiotics work for infections?” The answer is yes, if you use the right one for the right organism.
The LGG Evidence Base
Lactobacillus rhamnosus GG (LGG) is the most studied probiotic strain in human trials overall. Its IBS evidence is specific:
- A 2012 systematic review in Alimentary Pharmacology and Therapeutics found LGG modestly reduces abdominal pain in children with functional gut disorders, including IBS.
- Adult IBS evidence is less consistent. LGG appears more effective for IBS-D than IBS-C.
- A 2010 RCT (Francavilla et al, J Pediatr, PMID 19954811) found LGG significantly reduced pain frequency and severity in paediatric IBS vs placebo.
Caveat: LGG is Lactobacillus rhamnosus strain GG specifically. Studies on other Lactobacillus rhamnosus strains do not extend to LGG, and vice versa.
The B. infantis 35624 Evidence
Strain-by-Indication Evidence Matrix for IBS
| Strain | IBS Subtype | Evidence Level | Key Study |
|---|---|---|---|
| B. infantis 35624 | IBS-D | Strong | Whorwell et al, 2006, PMID 16863564 |
| L. plantarum 299v | IBS (mixed) | Moderate | Ducrotté et al, 2012, PMID 22844674 |
| L. rhamnosus GG | IBS-D (children) | Moderate | Francavilla et al, 2010, PMID 19954811 |
| B. lactis HN019 | IBS-C (transit) | Moderate | Waller et al, 2011, PMID 21696309 |
| VSL#3 (multi-strain) | IBS (various) | Moderate | Kim et al, 2005, PMID 15955196 |
| S. boulardii | Post-infectious IBS | Some evidence | Moré et al, 2015 |
What the Evidence Cannot Tell You
-
Effect sizes are modest: Most probiotic RCTs for IBS show 15-30% improvements in symptom severity scores vs placebo. This is statistically significant — but means probiotics are a complementary tool, not a cure. Low-FODMAP diet has a comparable or better evidence base for IBS-D.
-
Placebo response is high: IBS trials consistently show 30-40% placebo response rates. This makes it genuinely difficult to separate probiotic effect from expectation effect in individual cases.
-
Duration is underexplored: Most RCTs run 4-8 weeks. The long-term effect of sustained probiotic supplementation in IBS is not well-characterised.
-
Colonisation is transient: Most probiotic strains do not colonise permanently in the gut. Maldonado-Gómez et al (Cell Host Microbe 2016, PMID 27693307) showed LGG is detectable during supplementation but disappears within weeks of stopping. This does not mean probiotics are ineffective — it means the effect requires ongoing daily consumption, not a one-time intervention.
Practical Recommendations for IBS Sufferers
- Identify your IBS subtype first (IBS-D, IBS-C, IBS-M) — with your GP or gastroenterologist if possible. Different subtypes have different matched strains.
- For IBS-D: B. infantis 35624 (Align) is the most evidence-matched product at the lowest price point (approximately £29/30 capsules). LGG (Culturelle) is a reasonable alternative if Align is unavailable.
- For IBS-C: B. lactis HN019 (found in some Garden of Life formulations) has some evidence for transit time improvement.
- Run a minimum 8-week trial at the recommended dose before evaluating outcomes. IBS is variable — shorter trials are inconclusive.
- If nothing works after 8 weeks: Change the strain, not the dose. Dose-escalating a strain that is not matched to your indication will not produce better results.
- Combine with dietary management: The low-FODMAP diet has a robust evidence base for IBS-D (Gibson et al, Gut 2017, PMID 28592442). Probiotics and dietary management are complementary, not alternatives.
Bottom Line
Probiotics may support IBS symptom management — but only if the strain is matched to the IBS subtype. The evidence for B. infantis 35624 (IBS-D) and L. plantarum 299v (mixed IBS) is the strongest in the consumer product category. A 10B CFU single-strain product at £29/month is more likely to produce meaningful outcomes than a 100B CFU multi-strain blend at £50/month, if the strain is correctly matched.
Note: probiotic effects are strain-specific. A study on one Lactobacillus strain does not apply to other Lactobacillus strains. This is not medical advice — consult a healthcare professional before starting supplementation, especially if you are immunocompromised or pregnant.